Fast Five Quiz: Molecular and Biomarker Analysis in Non–Small Cell Lung Cancer (NSCLC)

Daniel S. Schwartz, MD

Disclosures

January 28, 2022

PD-L1 that is expressed on tumor cells can bind to ligands (such as programmed cell death protein 1 [PD-1]); this interaction effectively silences the T-cell response to an NSCLC tumor. Immune checkpoint inhibition is used to block the PD-1/PD-L1 interaction, thereby improving the antitumor effects of endogenous T cells.

ALK rearrangements, ROS1 rearrangements, and MET skipping mutations are all genetic abnormalities that may occur in NSCLC.

Learn more about molecular and biomarker analysis in NSCLC.

Editor's Recommendations

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....